navigatenash.com Open in urlscan Pro
162.244.66.81  Public Scan

Form analysis
2 forms found in the DOM

GET https://navigatenash.com/

<form autocomplete="off" role="search" method="get" id="searchform" class="searchform" action="https://navigatenash.com/">
  <div>
    <input type="text" value="" name="s" id="s" placeholder="Search">
    <input type="submit" id="searchsubmit" value="Search">
    <a class="search-toggle"><span class="icon-02"></span></a>
  </div>
</form>

GET https://navigatenash.com/

<form role="search" method="get" class="searchform" action="https://navigatenash.com/">
  <div>
    <input type="text" value="" name="s" placeholder="Search">
    <input type="submit" value="Search">
  </div>
</form>

Text Content

 * 
     Powered by Google Übersetzer
 * Investigator Portal
 * Portal

 * About NASH Cirrhosis
 * The NAVIGATE Study
 * About Clinical Trials
 * For Physicians

Open Menu
 * 
 * Investigator Portal
 * Portal


 * About NASH Cirrhosis
 * The NAVIGATE Study
 * About Clinical Trials
 * For Physicians

 1. 
 2. 
 3. 
 4. 


BRINGING HOPE TO THOSE WITH NASH CIRRHOSIS

The galectin-3 inhibitor belapectin is the first potential therapy to show
clinically significant effect in patients with NASH cirrhosis before the
development of esophageal varices.




THE ONLY PHASE 2B/3 CLINICAL TRIAL FOCUSED ON THE SYMPTOMS OF NASH CIRRHOSIS
INSTEAD OF LIVER BIOPSIES

There are currently no approved therapies for NASH cirrhosis, short of a liver
transplant.




THE PREVENTION OF VARICES ELIMINATES THE RISK OF BLEEDING VARICES

Bleeding varices threaten the life of cirrhotic patients.




APPROXIMATELY 50% OF CIRRHOTIC NASH PATIENTS WITH PORTAL HYPERTENSION DO NOT
HAVE VARICES WHEN FIRST EVALUATED

The development of varices is seen as the first sign of serious cirrhosis
complications.




WHAT IS NASH CIRRHOSIS?

NASH cirrhosis is the end stage of non-alcoholic steatohepatitis (NASH), where
scar tissue and regenerative nodules resulting from the inflammation and
fibrosis of NASH have replaced healthy liver tissue, preventing the liver from
functioning normally.

NASH cirrhosis will soon become the number one reason for liver transplants.

Learn More


WHAT IS THE NAVIGATE STUDY?

The NAVIGATE Study is the only adaptive Phase 2b/3 clinical trial focused on
NASH cirrhosis.

There is currently no treatment for NASH cirrhosis. The NAVIGATE Study seeks to
change this, offering patients and their families the first potential therapy
targeted specifically at NASH cirrhosis.

A previous clinical trial showed that a drug named belapectin may prevent the
development of esophageal varices in patients with compensated NASH cirrhosis.
Varices are an early sign for the development of serious complications in NASH
cirrhosis.

Learn More


DO I QUALIFY FOR THE NAVIGATE STUDY?

To be part of the study, you must have a confirmed diagnosis of NASH cirrhosis
with no evidence of esophageal varices.

Approximately 50% of cirrhotic NASH patients with portal hypertension do not
have varices when first diagnosed.

Learn More


WHAT IS A CLINICAL TRIAL?

Clinical trials are research studies involving human volunteers to see how safe
and effective a potential medication is in preventing, treating, or curing a
particular disease or condition.

There are substantial benefits to volunteering to be in a research study, but
participating isn’t right for everyone.

Learn More


FOR PHYSICIANS

The NAVIGATE Study has been designed to integrate the Standard of Care of NASH
cirrhosis patients.

Learn More




COVID-19 SAFETY

Galectin Therapeutics Inc. has developed several overarching principles to guide
its conduct of clinical research in light of COVID-19. Number one among these is
the safety of patients and study site personnel. Health authorities have
provided guidance for the conduct of clinical studies during this pandemic, and
we follow this guidance carefully. Participants are encouraged to contact their
study site directly with any questions or concerns.

 * About NASH Cirrhosis
 * The NAVIGATE Study
 * About Clinical Trials
 * For Physicians

 * Study Sponsor
 * Privacy Notice
 * Terms and Conditions
 * Compassionate Use Policy

Galectin Therapeutics
4960 Peachtree Industrial Boulevard
Suite 240
Norcross, Georgia 30071

Phone: 678-620-3186

 * 
 * 
 * 

© 2022 Galectin Therapeutics, Inc. All rights reserved.

This website is designed to assist patients and other people seeking general
information about clinical trials in nonalcoholic steatohepatitis (NASH)
cirrhosis. It is not intended to substitute for the medical advice of your
doctor or to enroll patients in any clinical trial. Please consult with your
doctor to determine the best treatment plan for you.




 * 
 * 
 * 
 * 
 * 
 * 
 * 
 * 







ORIGINALTEXT


Bessere Übersetzung vorschlagen

--------------------------------------------------------------------------------